A detailed history of Citigroup Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 57,833 shares of AVIR stock, worth $184,487. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,833
Previous 19,197 201.26%
Holding current value
$184,487
Previous $63,000 206.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.17 - $4.02 $122,476 - $155,316
38,636 Added 201.26%
57,833 $193,000
Q2 2024

Aug 12, 2024

BUY
$3.31 - $4.04 $14,630 - $17,856
4,420 Added 29.91%
19,197 $63,000
Q1 2024

May 10, 2024

BUY
$3.09 - $4.56 $7,057 - $10,415
2,284 Added 18.28%
14,777 $59,000
Q4 2023

Feb 09, 2024

BUY
$2.8 - $3.35 $31,970 - $38,250
11,418 Added 1062.14%
12,493 $38,000
Q3 2023

Nov 09, 2023

SELL
$3.0 - $3.79 $122,187 - $154,362
-40,729 Reduced 97.43%
1,075 $3,000
Q2 2023

Aug 10, 2023

BUY
$3.21 - $5.06 $125,103 - $197,203
38,973 Added 1376.65%
41,804 $156,000
Q1 2023

May 11, 2023

SELL
$3.0 - $4.97 $16,071 - $26,624
-5,357 Reduced 65.43%
2,831 $9,000
Q4 2022

Feb 09, 2023

SELL
$4.35 - $6.17 $48,802 - $69,221
-11,219 Reduced 57.81%
8,188 $39,000
Q3 2022

Nov 10, 2022

BUY
$5.49 - $8.79 $1,350 - $2,162
246 Added 1.28%
19,407 $110,000
Q2 2022

Aug 10, 2022

SELL
$5.33 - $8.18 $13,463 - $20,662
-2,526 Reduced 11.65%
19,161 $136,000
Q1 2022

May 12, 2022

SELL
$5.5 - $9.19 $106,040 - $177,183
-19,280 Reduced 47.06%
21,687 $157,000
Q4 2021

Feb 10, 2022

BUY
$7.67 - $44.59 $255,549 - $1.49 Million
33,318 Added 435.59%
40,967 $366,000
Q3 2021

Nov 10, 2021

BUY
$21.33 - $35.06 $163,153 - $268,173
7,649 New
7,649 $268,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.